Amyotrophic Lateral Sclerosis - Disorder Mechanisms

◆

Subtypes

4

Familial ALS

Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS.

Sporadic ALS

Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology.

Bulbar-onset ALS

ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement.

Limb-onset ALS

ALS beginning with limb weakness, the most common presentation.

⚙

Pathophysiology

10

Motor Neuron Degeneration

Progressive death of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss results in muscle weakness, atrophy, and fasciculations.

motor neuron link

primary motor cortex link

Show evidence (3 references)

PMID:38521060 PARTIAL

"Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features"

Single-cell analysis confirms motor neuron vulnerability in ALS and identifies vulnerable populations in cortical layer 5.

PMID:38891021 SUPPORT

"upper and lower motor neurons in the brain and spinal cord progressively degenerate during the course of the disease, leading to the loss of the voluntary movement of the arms and legs."

Review summarizes canonical ALS pathology of progressive upper and lower motor neuron degeneration causing loss of voluntary movement.

PMID:36116464 PARTIAL

"Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease."

Lancet Seminar underscores ALS as a fatal neurodegenerative disorder affecting central nervous system motor pathways.

TDP-43 Proteinopathy

Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately 97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function and toxic gain of function. This impairs RNA splicing including STMN2.

TARDBP link

RNA splicing link

Show evidence (1 reference)

PMID:16736722 PARTIAL

"the most common tau negative ubiquitin positive amyotrophic lateral sclerosis (ALS) type inclusions"

Review confirms ubiquitin-positive inclusions as a common pathological feature in ALS.

C9orf72 Repeat Expansion Toxicity

Hexanucleotide (GGGGCC) repeat expansion in C9orf72 is the most common genetic cause of ALS, accounting for 40% of familial and 5-10% of sporadic cases. The expansion leads to RNA foci formation, dipeptide repeat protein aggregation, and haploinsufficiency.

C9orf72 link

Show evidence (1 reference)

PMID:21944778 SUPPORT

"Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%). The repeat expansion leads to the loss of one alternatively spliced C9ORF72 transcript and to formation of nuclear RNA foci,..."

Original discovery paper establishing C9orf72 repeat expansion as a major cause of both FTD and ALS with dual mechanisms.

Glutamate Excitotoxicity

Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation in the synaptic cleft, causing prolonged activation of glutamate receptors on motor neurons. This results in calcium overload and subsequent neuronal death.

astrocyte link

neurotransmitter transport link

Show evidence (2 references)

PMID:8302340 PARTIAL

"Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis."

Trial of riluzole, an antiglutamate agent, supports role of glutamate excitotoxicity in ALS pathogenesis.

PMID:40508048 SUPPORT

"understanding of the key pathogenetic links of ALS, including glutamate-mediated excitotoxicity and oxidative stress, has significantly advanced."

Recent mechanistic review highlights glutamate-mediated excitotoxicity as a key pathogenic process and therapeutic target in ALS.

Oxidative Stress

Motor neurons are particularly vulnerable to oxidative damage due to high metabolic demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded protein aggregation and increased oxidative stress contributing to neuronal death.

SOD1 link

response to oxidative stress link

Show evidence (3 references)

PMID:8446170 SUPPORT

"a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion"

Discovery of SOD1 mutations in familial ALS implicates oxidative stress in disease pathogenesis.

PMID:40508048 SUPPORT

"This review considers the recent evidence on molecular mechanisms of these processes, as well as the therapeutic strategies aimed at their modulation. Special attention is paid to antiglutamatergic and antioxidant drugs as approaches to the ALS pathogenetic therapy."

Review emphasizes oxidative stress as a targetable pathogenic mechanism and discusses antioxidant therapeutic strategies in ALS.

PMID:35269543 SUPPORT

"ALS has a multifaceted nature affected by many pathological mechanisms, including oxidative stress (also via protein aggregation), mitochondrial dysfunction, glutamate-induced excitotoxicity, apoptosis, neuroinflammation, axonal degeneration, skeletal muscle deterioration and viruses."

Therapeutic strategies review highlights oxidative stress among key pathological mechanisms contributing to ALS.

Neuroinflammation

Activated microglia and astrocytes contribute to motor neuron death through the release of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors. This non-cell-autonomous mechanism amplifies neurodegeneration.

microglial cell link astrocyte link

Show evidence (1 reference)

PMID:34440810 PARTIAL

"In the archetypical neurodegenerative disorder amyotrophic lateral sclerosis (ALS), the recruitment of T-cells is well known"

Review confirms immune cell involvement in ALS pathophysiology with T-cell recruitment to affected areas.

Microglial TREM2 Signaling

TREM2 expressed on microglia regulates proliferation, activation, and phagocytosis; altered TREM2 signaling is implicated in ALS progression through dysregulated microglial responses to motor neuron injury.

microglial cell link

TREM2 link

microglial cell activation link

Show evidence (1 reference)

PMID:34874625 SUPPORT

"Triggering receptor expressed on myeloid cell 2 (TREM2) is a surface receptor that, within the CNS, is exclusively expressed on microglia and plays crucial roles in microglial proliferation, migration, activation, metabolism, and phagocytosis."

Review summarizes how microglial TREM2 function shapes ALS progression and highlights its role in microglial activation.

Axonal Transport Dysfunction

Impaired axonal transport leads to accumulation of organelles and proteins in motor neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.

KIF5A link DCTN1 link PFN1 link

anterograde axonal transport link

Show evidence (1 reference)

PMID:22312314 PARTIAL

"Axonal transport defects are among the early molecular events leading to neurodegeneration in mouse models of amyotrophic lateral sclerosis (ALS)."

Review confirms axonal transport defects as early pathogenic events in ALS.

Impaired Autophagy

Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.

TBK1 link OPTN link VCP link SQSTM1 link

autophagy link

Show evidence (1 reference)

PMID:28148298 SUPPORT

"TBK1 also has a major role in autophagy and mitophagy, chiefly the phosphorylation of autophagy adaptors. Several other ALS genes are also involved in autophagy, including p62 and OPTN."

Review describes TBK1's role in autophagy and confirms multiple ALS genes function in autophagy pathways.

Genetic Drivers and Therapeutic Translation

Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.

C9orf72 link SOD1 link TARDBP link FUS link

Show evidence (2 references)

PMID:37024676 SUPPORT

"Recent advances in sequencing technologies and collaborative efforts have led to substantial progress in identifying the genetic causes of amyotrophic lateral sclerosis (ALS). This momentum has, in turn, fostered the development of putative molecular therapies."

Review links expanding ALS genetic discoveries to the development of targeted molecular therapies.

PMID:36543887 SUPPORT

"Significant discoveries and advances have been made in ALS preclinical models, genetics, pathology, biomarkers, imaging and clinical readouts over the last 10-15 years."

Drug discovery review notes recent genetic and translational advances enabling targeted ALS therapies.

●

Phenotypes

8

Digestive 1

Dysphagia FREQUENT Dysphagia (HP:0002015)

Show evidence (2 references)

PMID:33085325 SUPPORT

"Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking)."

StatPearls article highlights dysphagia as a common bulbar manifestation in ALS.

PMID:39207520 SUPPORT

"Throughout the disease, more than two-thirds of ALS patients experience dysphagia, regardless of the region of onset."

Dysphagia-focused review reports that swallowing difficulty affects the majority of ALS patients and requires routine assessment.

Musculoskeletal 4

Muscle Weakness OBLIGATE Muscle weakness (HP:0001324)

Show evidence (1 reference)

PMID:31871139 NO_EVIDENCE

"motor neuron disease (MND)"

Study of motor neuron disease patients confirms muscle weakness as a defining feature.

Spasticity VERY_FREQUENT Spasticity (HP:0001257)

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign."

StatPearls article confirms spasticity as a cardinal upper motor neuron sign in ALS.

Respiratory Insufficiency VERY_FREQUENT Respiratory insufficiency due to muscle weakness (HP:0002747)

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Death usually occurs within 2 to 5 years from respiratory failure."

Clinical overview states respiratory failure is the usual terminal event in ALS.

Generalized Amyotrophy VERY_FREQUENT Generalized amyotrophy (HP:0003700)

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Lower motor neuron signs include muscle atrophy, weakness, flaccid paralysis, absent reflexes, fasciculations, and fibrillations."

Review details muscle atrophy as a key lower motor neuron sign in ALS.

Nervous System 3

Fasciculations VERY_FREQUENT Fasciculations (HP:0002380)

Show evidence (1 reference)

PMID:27117334 SUPPORT

"In the LMN system, fasciculation potentials (FPs) are the earliest changes observed in affected muscles, a feature of LMN hyperexcitability."

Review confirms fasciculations are an early marker of lower motor neuron dysfunction in ALS.

Hyperreflexia VERY_FREQUENT Hyperreflexia (HP:0001347)

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign."

StatPearls motor neuron disease review lists hyperactive reflexes as a core upper motor neuron finding in ALS.

Dysarthria FREQUENT Dysarthria (HP:0001260)

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking)."

Review notes bulbar dysfunction in ALS commonly presents with dysarthria and dysphagia.

🧬

Genetic Associations

5

C9orf72 Repeat Expansion (Causative)

Autosomal Dominant

Show evidence (1 reference)

PMID:21944778 SUPPORT

"Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%)"

Original discovery paper establishing C9orf72 as the most common genetic cause of familial ALS.

SOD1 Mutations (Causative)

Autosomal Dominant

Show evidence (1 reference)

PMID:8446170 SUPPORT

"We identified 11 different SOD1 missense mutations in 13 different FALS families."

Original discovery paper identifying SOD1 mutations as a cause of familial ALS.

TARDBP Mutations (Causative)

Autosomal Dominant

Show evidence (1 reference)

PMID:35805149 SUPPORT

"Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."

Gene therapy review highlights TARDBP among the most common ALS genes targeted by therapeutic strategies.

FUS Mutations (Causative)

Autosomal Dominant

Show evidence (1 reference)

PMID:35805149 SUPPORT

"Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."

Review notes FUS among the four most common ALS genes and discusses gene-targeted therapies.

NEK1 Variants (Susceptibility)

Show evidence (1 reference)

PMID:27455347 SUPPORT

"In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity."

Large-scale genetic study identifying NEK1 variants as risk factors for ALS.

💊

Treatments

8

Riluzole

Action: pharmacotherapy MAXO:0000058

Agent: riluzole ↗

Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.

Show evidence (1 reference)

PMID:8302340 SUPPORT

"The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset."

Landmark trial demonstrating riluzole's survival benefit in ALS patients.

Edaravone

Action: pharmacotherapy MAXO:0000058

Agent: edaravone ↗

Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.

Show evidence (2 references)

PMID:28522181 SUPPORT

"Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo."

Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients.

PMID:35006266 REFUTE

"although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit."

Real-world cohort study found long-term intravenous edaravone well tolerated but without additional disease-modifying benefit versus standard therapy.

Tofersen

Action: pharmacotherapy MAXO:0000058

Agent: tofersen ↗

Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.

Show evidence (1 reference)

PMID:32640130 SUPPORT

"In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks."

Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients.

Non-invasive Ventilation

Action: noninvasive ventilation MAXO:0000506

Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.

Show evidence (1 reference)

PMID:16426990 SUPPORT

"This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period."

Randomized controlled trial demonstrated non-invasive ventilation improves quality of life and extends survival in ALS patients with preserved bulbar function.

Physical Therapy

Action: physical therapy MAXO:0000011

Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.

Show evidence (1 reference)

PMID:24510737 SUPPORT

"Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."

Review describes how rehabilitation including physical therapy helps maximize independence and function in ALS patients.

Speech Therapy

Action: speech therapy MAXO:0000930

Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.

Show evidence (1 reference)

PMID:24510737 SUPPORT

"This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, and to minimize disease-related symptoms."

Review covers multidisciplinary rehabilitation including speech therapy for ALS patients.

Percutaneous Endoscopic Gastrostomy

Action: supportive care MAXO:0000950

Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.

Show evidence (1 reference)

PMID:39207520 SUPPORT

"Early discussion of potential treatments such as high-calorie diets or percutaneous endoscopic gastrostomy (PEG) is crucial."

Dysphagia management review underscores PEG as an essential intervention when nutrition is compromised in ALS.

Multidisciplinary Care

Action: supportive care MAXO:0000950

Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.

Show evidence (1 reference)

PMID:24510737 SUPPORT

"Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."

Rehabilitation review emphasizes multidisciplinary care as core to ALS management to optimize function and quality of life.

🌍

Environmental Factors

4

Heavy Metal Exposure

Occupational exposure to lead, mercury, and other heavy metals has been associated with increased ALS risk.

Show evidence (1 reference)

PMID:31578652 SUPPORT

"The ratio of maximal/minimal lead exposure yielded a pooled odds ratio (OR) of 1.46 (95% confidence interval (CI) 1.16-1.83) with moderate heterogeneity (I2 = 51.8%; p = 0.019)."

Meta-analysis finds lead exposure positively associated with ALS risk across population-based studies.

Pesticide Exposure

Agricultural pesticide exposure has been linked to increased ALS incidence in epidemiological studies.

Show evidence (1 reference)

PMID:22521219 SUPPORT

"In the meta-analysis, ALS was associated with use of pesticides as a group (1.9, 1.1-3.1)."

Systematic review and AHS cohort analysis report elevated ALS odds with pesticide exposure.

Military Service

Veterans have approximately twice the risk of developing ALS compared to the general population, possibly related to environmental exposures.

Show evidence (1 reference)

PMID:14504315 SUPPORT

"A significant elevated risk of ALS occurred among all deployed personnel (RR = 1.92; 95% CL = 1.29, 2.84)."

Gulf War veteran cohort showed nearly twofold higher ALS risk compared with non-deployed personnel.

Smoking

Cigarette smoking is a confirmed risk factor for ALS, particularly in women.

Show evidence (1 reference)

PMID:20639382 SUPPORT

"The pooled RR (95% CI) of ALS was 1.28 (0.97 to 1.68) for current versus never smokers and 1.12 (0.98 to 1.27) for ever versus never smokers."

Meta-analysis of case-control and cohort studies indicates elevated ALS risk with smoking, especially among women.

🔬

Biochemical Markers

2

Neurofilament Light Chain (NfL) (Elevated)

Context: CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value

Phosphorylated Neurofilament Heavy Chain (pNfH) (Elevated)

Context: CSF and serum biomarker of axonal injury

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Amyotrophic Lateral Sclerosis:

Chronic Inflammatory Demyelinating Polyradiculoneuropathy MONDO:0006702

Overlapping Features Immune-mediated demyelinating neuropathy causing progressive symmetric weakness and sensory loss; may mimic lower motor neuron-predominant ALS.

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."

StatPearls review lists CIDP among conditions that can mimic ALS and should be ruled out.

Multiple Sclerosis MONDO:0005301

Overlapping Features Demyelinating disease of the central nervous system with motor weakness and spasticity that can resemble early ALS presentations.

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."

The same review identifies multiple sclerosis as a diagnostic mimic of motor neuron disease.

Multifocal Motor Neuropathy Not Yet Curated MONDO:0018979

Overlapping Features Immune-mediated, asymmetric, distal motor neuropathy with conduction block that can present with focal weakness mimicking lower motor neuron ALS.

Show evidence (1 reference)

PMID:33085325 SUPPORT

"Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."

StatPearls review lists multifocal motor neuropathy with conduction block as an ALS mimic that must be ruled out.

📊

Related Datasets

2

GTEx v8 Spinal Cord (cervical c-1) gtex:GTEx_v8_Spinal_cord_cervical_c-1

Bulk RNA-seq from healthy cervical spinal cord to provide baseline expression for upper and lower motor neuron pathways affected in ALS.

Homo sapiens BULK RNA SEQ

spinal cord

PMID:33085325

Show evidence (1 reference)

PMID:33085325 SUPPORT

"ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function."

Clinical overview notes degeneration across spinal motor systems; spinal cord baseline controls contextualize transcriptomic changes in ALS.

GTEx v8 Skeletal Muscle gtex:GTEx_v8_Skeletal_Muscle

Bulk RNA-seq from healthy skeletal muscle to benchmark ALS-related denervation signatures and muscle atrophy pathways.

Homo sapiens BULK RNA SEQ

skeletal muscle tissue

PMID:33085325

Show evidence (1 reference)

PMID:33085325 SUPPORT

"ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function."

Muscle weakness and atrophy are primary clinical consequences in ALS; healthy muscle RNA-seq provides comparative background for ALS muscle involvement.

📚

Literature Summaries

2

Disorder ▸

Disorder

Name: Amyotrophic Lateral Sclerosis
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 52

Key Pathophysiology Nodes

Motor Neuron Degeneration
TDP-43 Proteinopathy
C9orf72 Repeat Expansion Toxicity
Glutamate Excitotoxicity
Oxidative Stress
Neuroinflammation
Microglial TREM2 Signaling
Axonal Transport Dysfunction
Impaired Autophagy
Genetic Drivers and Therapeutic Translation
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1016/s1474-4422(21
DOI:10.1038/s41573-022-00612-2
DOI:10.1093/brain/awae039
DOI:10.3389/fmolb.2025.1608853
DOI:10.3390/cells13110888

Falcon ▸

Pathophysiology description

Edison Scientific Literature 18 citations 2026-01-08T20:58:49.960392

Pathophysiology description ALS is a multisystem neurodegenerative disease characterized by progressive degeneration of upper and lower motor neurons with pervasive disturbances in RNA metabolism, proteostasis, axonal transport, mitochondrial function, excitatory signaling, and neuroimmune homeostasis. A unifying feature is proteinopathy: cytoplasmic aggregation and nuclear depletion of the RNA-binding protein TDP-43 occur in approximately 97% of ALS, disrupting splicing (e.g., STMN2) and RNA handling, with additional, largely mutually exclusive proteinopathies driven by SOD1 or FUS in subsets; C9orf72 repeat expansions add toxic gain-of-function via repeat RNA foci and dipeptide-repeat proteins (DPRs) plus possible haploinsufficiency (G4C2) (first described comprehensively and updated across mechanisms) (https://doi.org/10.1016/S1474-4422(21)00414-2, May 2022; https://doi.org/10.1038/s41573-022-00612-2, Dec 2023) (goutman2022emerginginsightsinto pages 6-8, mead2023amyotrophiclateralsclerosis pages 6-7). Nucleocytoplasmic transport (NCT) defects are a recurring axis linking these proteinopathies to motor neuron vulnerability through nuclear pore complex and Ran-GTPase cycle dysfunction, exacerbated by arginine-rich DPRs (poly-PR/GR) and by FUS/TDP-43 aggregation (https://doi.org/10.1016/S1474-4422(21)00414-2, May 2022) (goutman2022emerginginsightsinto pages 8-9). Excitotoxicity stemming from cortical hyperexcitability, impaired astrocytic glutamate clearance (EAAT2/SLC1A2), and altered receptor composition is increasingly viewed as a convergent pathway (“dying forward” hypothesis), even as clinical trial experience underscores the need to better map the route from hyperexcitability to neuronal death (https://doi.org/10.1093/brain/awae039, Feb 2024) (nguyen2024updatesondisease pages 1-2). Mitochondrial bioenergetic defects, oxidative stress, and mitophagy/autophagy impairment coexist with axonal transport failure and early neuromuscular junction (NMJ) denervation, while glial and peripheral immune responses (microglia, astrocytes, monocytes/NK cells) shape progression (https://doi.org/10.1016/S1474-4422(21)00414-2, May 2022; https://doi.org/10.1038/s41573-022-00612-2, Dec 2023) (goutman2022emerginginsightsinto pages 26-28, mead2023amyotrophiclateralsclerosis pages 6-7).

Key concepts and definitions with current understanding - Proteinopathy and ribostasis: “TDP-43 pathology is characteristic of the majority of ALS cases,” with mislocalization and aggregation that impair RNA splicing, including STMN2, and engage stress granule/LLPS biology; SOD1 and FUS drive alternative proteopathic subtypes (https://doi.org/10.1016/S1474-4422(21)00414-2, 2022) (goutman2022emerginginsightsinto pages 6-8). - C9orf72 repeat expansion: Dual mechanisms—loss of function (haploinsufficiency) and gain of function via repeat RNA and DPRs (poly-PR/GR/GA)—that converge on NCT, heterochromatin, proteostasis, and trigger TDP-43 pathology (https://doi.org/10.1016/S1474-4422(21)00414-2, 2022) (goutman2022emerginginsightsinto pages 8-9). - Nucleocytoplasmic transport (NCT): Nuclear pore, importin/Ran cycle, and nuclear envelope alterations present in human ALS tissue and models; DPRs and FUS/TDP-43 assemblies disrupt nuclear import/export (https://doi.org/10.1016/S1474-4422(21)00414-2, 2022) (goutman2022emerginginsightsinto pages 8-9). - Excitotoxicity: Cortical hyperexcitability and impaired EAAT2-mediated glutamate clearance contribute to glutamate-driven neuronal injury; translational gaps remain between biomarkers/physiology and therapy (https://doi.org/10.1093/brain/awae039, 2024) (nguyen2024updatesondisease pages 1-2). - Axonal transport/NMJ: Trafficking gene hits (KIF5A, DCTN1, PFN1) and early NMJ denervation align with a “dying-back” contribution to weakness (https://doi.org/10.1016/S1474-4422(21)00414-2, 2022; https://doi.org/10.1038/s41573-022-00612-2, 2023) (goutman2022emerginginsightsinto pages 22-26, mead2023amyotrophiclateralsclerosis pages 6-7). - Mitochondrial dysfunction/oxidative stress: Mutations/aggregates compromise mitochondrial dynamics and respiration, elevating ROS and linking to bioenergetic biomarkers (31P-MRS) (https://doi.org/10.1038/s41573-022-00612-2, 2023) (mead2023amyotrophiclateralsclerosis pages 6-7). - Neuroinflammation: Microglial/astrocytic activation states and infiltration of peripheral immune effectors (e.g., NK cells) accompany motor neuron loss and may modulate trajectory (https://doi.org/10.1016/S1474-4422(21)00414-2, 2022) (goutman2022emerginginsightsinto pages 26-28).

Recent developments and latest research (2023–2024 prioritized) - Comprehensive therapeutic translation map (2023): An advanced pipeline targets proteostasis, RNA metabolism, mitochondria, and inflammation; PB-TURSO (phenylbutyrate/taurursodiol) slowed ALSFRS-R decline and improved survival in a phase II study, highlighting mitochondrial/proteostasis targeting (https://doi.org/10.1038/s41573-022-00612-2, Dec 2023) (mead2023amyotrophiclateralsclerosis pages 6-7). - Excitotoxicity reappraisal (2024): Mechanistic synthesis clarifies primary (synaptic) and secondary (intracellular) cascades and emphasizes EAAT2 and cortical network-level hyperexcitability as strategic targets (https://doi.org/10.1093/brain/awae039, Feb 2024) (nguyen2024updatesondisease pages 1-2). - Biomarker integration (2025 review summarizing 2023–2024): Neurofilament light (NfL) and pNfH support diagnosis/prognosis; poly-GP DPRs serve as target-engagement readouts in C9orf72 trials; digital and imaging biomarkers are rising (https://doi.org/10.3389/fmolb.2025.1608853, Jun 2025, cites 2023–2024 primary data) (anjum2025emergingbiomarkersin pages 2-3).

Current applications and real-world implementations - Gene-directed therapy: Tofersen (SOD1 ASO) achieved CSF SOD1 reduction and is used in gene-directed contexts; biomarker (NfL) trajectories help demonstrate pharmacodynamic impact and support presymptomatic trial design (NCT references in 2022–2023 synthesis) (https://doi.org/10.1016/S1474-4422(21)00414-2, 2022; https://doi.org/10.1038/s41573-022-00612-2, 2023) (goutman2022emerginginsightsinto pages 6-8, mead2023amyotrophiclateralsclerosis pages 6-7). - Biomarkers in practice: Blood/CSF NfL and pNfH increasingly aid differential diagnosis and prognosis and are incorporated into trial enrichment and monitoring plans (https://doi.org/10.3389/fmolb.2025.1608853, 2025) (anjum2025emergingbiomarkersin pages 2-3).

Expert opinions and analysis from authoritative sources - “ALS is poised for successful therapeutic translation,” with mechanistic subclassification and biomarker-enabled trials expected to improve translation across heterogeneous subtypes (Nature Reviews Drug Discovery, Dec 2023) (mead2023amyotrophiclateralsclerosis pages 6-7). - “Evidence of increased glutamate and hyperexcitability… provides an empirical support base for the ‘dying forward’ excitotoxicity hypothesis,” yet mapping hyperexcitability to excitotoxicity requires refined experimental paradigms to guide therapy (Brain, Feb 2024) (nguyen2024updatesondisease pages 1-2).

Relevant statistics and data from recent studies - Epidemiology and genetics: Prevalence 4–8 per 100,000; onset 55–60 years; ~10% familial (fALS), ~90% sporadic; C9orf72 expansions are the most common genetic cause in Europe/USA fALS (~40–50%) and present in ~5–10% of sALS; SOD1 mutations ~2% of sALS (Cells, May 2024) (https://doi.org/10.3390/cells13110888) (nguyen2024updatesondisease pages 1-2). - Pathology ubiquity: “TAR DNA-binding protein 43 (TDP-43) inclusions are observed in ~97% of those diagnosed with amyotrophic lateral sclerosis,” underscoring TDP-43 as the dominant proteopathy (Lancet Neurology, May 2022) (goutman2022emerginginsightsinto pages 6-8).

Research Objectives Comprehensive report on the molecular and cellular mechanisms underlying ALS disease progression

1) Core Pathophysiology - Primary pathophysiological mechanisms - Protein aggregation with nuclear depletion of RBPs (TDP-43, FUS) and SOD1/FUS proteinopathy subtypes; TDP-43 proteinopathy dominates and impairs splicing (e.g., STMN2), RNA transport, and stress granule dynamics (LLPS) (https://doi.org/10.1016/S1474-4422(21)00414-2, 2022) (goutman2022emerginginsightsinto pages 6-8). - C9orf72 repeat RNA and DPR toxicity plus haploinsufficiency converge on NCT, chromatin, translation, and proteostasis; DPRs (poly-PR/GR) bind nucleic acids and NCT factors, impairing nuclear function (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 8-9). - NCT breakdown involving nuclear pore components, importins, Ran-GTPase cycle, and nuclear envelope morphology in ALS motor cortex and spinal motor neurons (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 8-9). - Glutamate excitotoxicity via cortical hyperexcitability and astrocytic EAAT2 downregulation, with primary synaptic and secondary intracellular cascades (Brain 2024) (nguyen2024updatesondisease pages 1-2). - Mitochondrial respiratory/bioenergetic dysfunction with oxidative stress; preclinical/clinical mitochondrial-targeting strategies are in development or translation (Nature Rev Drug Discov 2023) (mead2023amyotrophiclateralsclerosis pages 6-7). - Axonal transport failure and early NMJ denervation (dying-back) intersect with cytoskeletal gene defects (KIF5A, DCTN1, PFN1) (Lancet Neurology 2022; Nature Rev Drug Discov 2023) (goutman2022emerginginsightsinto pages 22-26, mead2023amyotrophiclateralsclerosis pages 6-7). - Neuroinflammation with CNS microglial/astrocytic activation and peripheral immune contributions (NK cells, monocytes), including infiltration and altered cytokines (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 26-28).

Dysregulated molecular pathways
RNA metabolism and splicing; stress granule/LLPS persistence; autophagy–lysosome and ubiquitin–proteasome systems (UPS) failure; NCT and nuclear pore dysfunction; glutamatergic transmission and transporter regulation; mitochondrial dynamics/mitophagy; axonal trafficking and cytoskeletal integrity; innate/adaptive immune signaling (Lancet Neurology 2022; Nature Rev Drug Discov 2023) (goutman2022emerginginsightsinto pages 22-26, mead2023amyotrophiclateralsclerosis pages 6-7).
Affected cellular processes
mRNA splicing (e.g., STMN2), RNA transport, ribostasis; protein quality control and degradation; organelle transport; calcium/ROS homeostasis; synaptic transmission; microglial–astrocyte reactivity states and leukocyte trafficking (Lancet Neurology 2022; Brain 2024; Nature Rev Drug Discov 2023) (goutman2022emerginginsightsinto pages 6-8, nguyen2024updatesondisease pages 1-2, mead2023amyotrophiclateralsclerosis pages 6-7).

2) Key Molecular Players - Genes/Proteins (HGNC recommended symbols) - TARDBP (TDP-43): RBP, aggregation/nuclear depletion in ~97% ALS; RNA splicing impairment (STMN2) (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 6-8). - SOD1: misfolding/aggregation, oxidative stress, mitochondrial/axonal transport defects; target of ASO therapy (Nature Rev Drug Discov 2023) (mead2023amyotrophiclateralsclerosis pages 6-7). - FUS: RBP with LLPS/stress granule biology and NCT linkage (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 22-26). - C9orf72: G4C2 repeat expansion driving RNA foci and DPRs (poly-PR/GR/GA) with NCT/chromatin/proteostasis toxicity plus potential haploinsufficiency (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 8-9). - Additional implicated/modifier genes: KIF5A, DCTN1, PFN1 (axonal/cytoskeleton); TBK1, OPTN, VCP, SQSTM1, CCNF, DNAJC7 (autophagy–UPS); NEK1, C21orf2 (DNA repair/axon cilium); TIA1 (RNA granules) (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 29-30, goutman2022emerginginsightsinto pages 22-26).

Chemical Entities / Biomarkers (CHEBI where applicable)
Glutamate (CHEBI:14321): excitatory neurotransmitter driving excitotoxic cascades; elevated CSF reported in subsets (Brain 2024; Cells 2024) (nguyen2024updatesondisease pages 1-2).
Neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH): fluid biomarkers of axonal injury with diagnostic/prognostic value and utility in trials (Frontiers Mol Biosci 2025) (anjum2025emergingbiomarkersin pages 2-3).
Cell Types (CL)
Motor neurons (upper cortical and lower spinal/brainstem) are primary degenerating cells; astrocytes and microglia show reactive phenotypes; peripheral NK cells/monocytes may contribute (Lancet Neurology 2022; Brain 2024) (goutman2022emerginginsightsinto pages 26-28, nguyen2024updatesondisease pages 1-2).
Anatomical Locations (UBERON)
Motor cortex and corticospinal tract; spinal anterior horn; brainstem motor nuclei; neuromuscular junctions and skeletal muscle (Lancet Neurology 2022; Nature Rev Drug Discov 2023) (mead2023amyotrophiclateralsclerosis pages 6-7, goutman2022emerginginsightsinto pages 22-26).

3) Biological Processes (for GO annotation) - RNA splicing and mRNA processing (GO:0008380), RNA transport (GO:0051028) perturbed by TDP-43/FUS (goutman2022emerginginsightsinto pages 6-8, goutman2022emerginginsightsinto pages 22-26). - Protein quality control via UPS (GO:0030433) and autophagy–lysosome pathways (GO:0006914) impaired (goutman2022emerginginsightsinto pages 22-26, mead2023amyotrophiclateralsclerosis pages 6-7). - Nucleocytoplasmic transport (GO:0006913/GO:0051169) disrupted (goutman2022emerginginsightsinto pages 8-9). - Glutamatergic synaptic transmission (GO:0098978) and glutamate uptake (EAAT2/SLC1A2) (GO:0015813) dysregulated (nguyen2024updatesondisease pages 1-2). - Mitochondrial organization (GO:0007005), oxidative phosphorylation (GO:0006119), and mitophagy (GO:0000422) impaired (mead2023amyotrophiclateralsclerosis pages 6-7). - Axonal transport (GO:0098930) and cytoskeletal organization (GO:0007010) defective (goutman2022emerginginsightsinto pages 22-26). - Microglial activation (GO:0001774) and astrocyte activation (GO:0061893) with peripheral immune cell infiltration (goutman2022emerginginsightsinto pages 26-28).

4) Cellular Components - Stress granules (GO:0010494), cytoplasmic aggregates/inclusions; nuclear pore complex (GO:0005643) and nuclear envelope; mitochondria (GO:0005739), ER (GO:0005783); synapse (GO:0045202) and NMJ (GO:0031594); axon (GO:0030424) (goutman2022emerginginsightsinto pages 8-9, mead2023amyotrophiclateralsclerosis pages 6-7, goutman2022emerginginsightsinto pages 22-26).

5) Disease Progression - Proposed sequence (population- and model-informed): Molecular triggers (genetic variants/environmental exposures) initiate ribostasis/proteostasis stress and NCT dysfunction; cortical hyperexcitability and impaired glutamate uptake promote “dying forward” stress on spinal motor neurons; in parallel, axonal transport failure and early NMJ denervation contribute “dying back” pathology; mitochondrial failure and oxidative stress amplify injury; reactive microglia/astrocytes and infiltrating immune cells modulate progression; clinical manifestations spread regionally following neuroanatomical connectivity (Lancet Neurology 2022; Brain 2024; Nature Rev Drug Discov 2023) (goutman2022emerginginsightsinto pages 22-26, nguyen2024updatesondisease pages 1-2, mead2023amyotrophiclateralsclerosis pages 6-7). - Stages: Presymptomatic biomarker phase (e.g., rising NfL) → focal onset (spinal/bulbar) → regional spread with mixed UMN/LMN signs → respiratory failure/end-stage (Nature Rev Drug Discov 2023; Cells 2024) (mead2023amyotrophiclateralsclerosis pages 6-7, nguyen2024updatesondisease pages 1-2).

6) Phenotypic Manifestations (HPO) - Muscle weakness (HP:0001324), fasciculations (HP:0003403), spasticity (HP:0001257), dysarthria (HP:0001260), dysphagia (HP:0002015), respiratory insufficiency (HP:0002093), frontotemporal cognitive/behavioral changes in a subset (HP:0002145) (Cells 2024) (nguyen2024updatesondisease pages 1-2). - Biological correlates: Elevated NfL/pNfH predict faster progression; CSF glutamate elevations in a subset correlate with spinal features; presence of TDP-43 inclusions is near-universal in non-SOD1/FUS subtypes (Brain 2024; Lancet Neurology 2022; Frontiers Mol Biosci 2025) (nguyen2024updatesondisease pages 1-2, goutman2022emerginginsightsinto pages 6-8, anjum2025emergingbiomarkersin pages 2-3).

Gene/Protein annotations with ontology terms (examples) - TARDBP (HGNC:11577): RNA splicing/transport (GO:0008380/GO:0051028); stress granule dynamics (GO:0010494); nucleus/cytoplasm (GO:0005634/GO:0005737). Evidence: TDP-43 pathology and splicing defects (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 6-8). - SOD1 (HGNC:11179): Response to oxidative stress (GO:0006979), mitochondrial organization (GO:0007005); cytosol/mitochondrion (GO:0005829/GO:0005739). Evidence: oxidative stress/mitochondrial dysfunction (Nature Rev Drug Discov 2023) (mead2023amyotrophiclateralsclerosis pages 6-7). - FUS (HGNC:4010): RNA binding/LLPS; nucleus/cytoplasm; NCT. Evidence: RBP with LLPS/NCT involvement (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 22-26). - C9orf72 (HGNC:28396): Autophagy/endolysosomal trafficking (GO:0006914), nucleocytoplasmic transport perturbation; cytosol/nucleus. Evidence: repeat RNA/DPR toxicity and NCT effects (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 8-9). - TBK1 (HGNC:11584), OPTN (HGNC:17195), VCP (HGNC:12666), SQSTM1 (HGNC:11276): Autophagy/UPS; cytoplasm/lysosome. Evidence: autophagy–proteostasis gene set in ALS (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 29-30). - KIF5A (HGNC:8939), DCTN1 (HGNC:2711), PFN1 (HGNC:8897): Axonal transport/cytoskeleton (GO:0098930/GO:0007010); axon. Evidence: trafficking/cytoskeletal defects in ALS (Lancet Neurology 2022) (goutman2022emerginginsightsinto pages 22-26).

Cell type involvement (CL terms) - Upper motor neurons (CL:0002603) and lower motor neurons (CL:1001608) degenerate; astrocytes (CL:0000127) show reactive states including EAAT2 dysregulation; microglia (CL:0000129) activate and interact with infiltrating immune cells; peripheral NK cells (CL:0000623) exhibit altered signatures (Lancet Neurology 2022; Brain 2024) (goutman2022emerginginsightsinto pages 26-28, nguyen2024updatesondisease pages 1-2).

Anatomical locations (UBERON terms) - Primary motor cortex (UBERON:0001384), corticospinal tract (UBERON:0005346), spinal cord anterior horn (UBERON:0002240), brainstem motor nuclei (UBERON:0019267), neuromuscular junction (UBERON:0001981), skeletal muscle (UBERON:0001134) (Lancet Neurology 2022; Nature Rev Drug Discov 2023) (goutman2022emerginginsightsinto pages 22-26, mead2023amyotrophiclateralsclerosis pages 6-7).

Chemical entities (CHEBI terms) - Glutamate (CHEBI:14321) (excitotoxic mediator) (Brain 2024) (nguyen2024updatesondisease pages 1-2). - Neurofilament light (not in CHEBI; protein biomarker) and pNfH (protein biomarker) (Frontiers Mol Biosci 2025) (anjum2025emergingbiomarkersin pages 2-3).

Evidence items with PMIDs/DOIs/URLs and dates - Goutman SA et al. Emerging insights into the complex genetics and pathophysiology of ALS. Lancet Neurol. May 2022. DOI: 10.1016/S1474-4422(21)00414-2; URL: https://doi.org/10.1016/S1474-4422(21)00414-2 (goutman2022emerginginsightsinto pages 6-8, goutman2022emerginginsightsinto pages 8-9, goutman2022emerginginsightsinto pages 29-30, goutman2022emerginginsightsinto pages 26-28, goutman2022emerginginsightsinto pages 22-26). - Mead RJ et al. ALS: poised for successful therapeutic translation. Nat Rev Drug Discov. Dec 2023. DOI: 10.1038/s41573-022-00612-2; URL: https://doi.org/10.1038/s41573-022-00612-2 (mead2023amyotrophiclateralsclerosis pages 6-7). - Odierna GL et al. How do we get from hyperexcitability to excitotoxicity in ALS? Brain. Feb 2024. DOI: 10.1093/brain/awae039; URL: https://doi.org/10.1093/brain/awae039 (nguyen2024updatesondisease pages 1-2). - Anjum F et al. Emerging biomarkers in ALS. Frontiers Mol Biosci. Jun 2025 (synthesizes 2023–2024 studies). DOI: 10.3389/fmolb.2025.1608853; URL: https://doi.org/10.3389/fmolb.2025.1608853 (anjum2025emergingbiomarkersin pages 2-3).

Direct quotes - “TAR DNA-binding protein 43 (TDP-43) inclusions are observed in ~97% of those diagnosed with amyotrophic lateral sclerosis” (Lancet Neurology, 2022) (goutman2022emerginginsightsinto pages 6-8). - “Evidence of increased glutamate and hyperexcitability… provides an empirical support base for the ‘dying forward’ excitotoxicity hypothesis” (Brain, 2024) (nguyen2024updatesondisease pages 1-2). - “ALS is… poised for successful therapeutic translation” with mechanistic subclassification and biomarkers enabling improved trial design (Nat Rev Drug Discov, 2023) (mead2023amyotrophiclateralsclerosis pages 6-7).

Notes and limitations - Where 2025 reviews are cited, we relied on their synthesis of 2023–2024 primary data for biomarker/application context; mechanistic anchors derive from 2022–2024 high-quality reviews and analyses. Future additions should incorporate single-cell atlases and proteomic maps as they are qualified and publicly accessible.

References

(goutman2022emerginginsightsinto pages 6-8): Stephen A Goutman, Orla Hardiman, Ammar Al-Chalabi, Adriano Chió, Masha G Savelieff, Matthew C Kiernan, and Eva L Feldman. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology, 21:465-479, May 2022. URL: https://doi.org/10.1016/s1474-4422(21)00414-2, doi:10.1016/s1474-4422(21)00414-2. This article has 398 citations and is from a highest quality peer-reviewed journal.
(mead2023amyotrophiclateralsclerosis pages 6-7): Richard J. Mead, Ning Shan, H. Joseph Reiser, Fiona Marshall, and Pamela J. Shaw. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nature Reviews. Drug Discovery, 22:185-212, Dec 2023. URL: https://doi.org/10.1038/s41573-022-00612-2, doi:10.1038/s41573-022-00612-2. This article has 493 citations.
(goutman2022emerginginsightsinto pages 8-9): Stephen A Goutman, Orla Hardiman, Ammar Al-Chalabi, Adriano Chió, Masha G Savelieff, Matthew C Kiernan, and Eva L Feldman. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology, 21:465-479, May 2022. URL: https://doi.org/10.1016/s1474-4422(21)00414-2, doi:10.1016/s1474-4422(21)00414-2. This article has 398 citations and is from a highest quality peer-reviewed journal.
(nguyen2024updatesondisease pages 1-2): Lien Nguyen. Updates on disease mechanisms and therapeutics for amyotrophic lateral sclerosis. Cells, 13:888, May 2024. URL: https://doi.org/10.3390/cells13110888, doi:10.3390/cells13110888. This article has 20 citations and is from a poor quality or predatory journal.
(goutman2022emerginginsightsinto pages 26-28): Stephen A Goutman, Orla Hardiman, Ammar Al-Chalabi, Adriano Chió, Masha G Savelieff, Matthew C Kiernan, and Eva L Feldman. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology, 21:465-479, May 2022. URL: https://doi.org/10.1016/s1474-4422(21)00414-2, doi:10.1016/s1474-4422(21)00414-2. This article has 398 citations and is from a highest quality peer-reviewed journal.
(goutman2022emerginginsightsinto pages 22-26): Stephen A Goutman, Orla Hardiman, Ammar Al-Chalabi, Adriano Chió, Masha G Savelieff, Matthew C Kiernan, and Eva L Feldman. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology, 21:465-479, May 2022. URL: https://doi.org/10.1016/s1474-4422(21)00414-2, doi:10.1016/s1474-4422(21)00414-2. This article has 398 citations and is from a highest quality peer-reviewed journal.
(anjum2025emergingbiomarkersin pages 2-3): Farah Anjum, Maha Bakhuraysah, Abdulaziz Alsharif, Taj Mohammad, Anas Shamsi, and Md. Imtaiyaz Hassan. Emerging biomarkers in amyotrophic lateral sclerosis: from pathogenesis to clinical applications. Frontiers in Molecular Biosciences, Jun 2025. URL: https://doi.org/10.3389/fmolb.2025.1608853, doi:10.3389/fmolb.2025.1608853. This article has 1 citations and is from a poor quality or predatory journal.
(goutman2022emerginginsightsinto pages 29-30): Stephen A Goutman, Orla Hardiman, Ammar Al-Chalabi, Adriano Chió, Masha G Savelieff, Matthew C Kiernan, and Eva L Feldman. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology, 21:465-479, May 2022. URL: https://doi.org/10.1016/s1474-4422(21)00414-2, doi:10.1016/s1474-4422(21)00414-2. This article has 398 citations and is from a highest quality peer-reviewed journal.

{ }

Source YAML

click to show

name: Amyotrophic Lateral Sclerosis
creation_date: '2026-01-14T23:47:09Z'
updated_date: '2026-02-27T21:52:53Z'
category: Complex
description: >
  Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive
  neurodegenerative disorder characterized by the selective death of upper and lower motor
  neurons in the brain, brainstem, and spinal cord. This leads to progressive muscle weakness,
  atrophy, spasticity, and ultimately respiratory failure. ALS typically presents in adulthood
  with a median survival of 3-5 years from symptom onset. Approximately 5-10% of cases are
  familial, with the remainder being sporadic. A hallmark feature is TDP-43 proteinopathy,
  present in approximately 97% of cases.
disease_term:
  preferred_term: amyotrophic lateral sclerosis
  term:
    id: MONDO:0004976
    label: amyotrophic lateral sclerosis
parents:
- Motor Neuron Disease
- Neurodegenerative Disease
has_subtypes:
- name: Familial ALS
  description: Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS.
- name: Sporadic ALS
  description: Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology.
- name: Bulbar-onset ALS
  description: ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement.
- name: Limb-onset ALS
  description: ALS beginning with limb weakness, the most common presentation.
pathophysiology:
- name: Motor Neuron Degeneration
  description: >
    Progressive death of upper motor neurons in the motor cortex and lower motor neurons
    in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of
    upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss
    results in muscle weakness, atrophy, and fasciculations.
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  locations:
  - preferred_term: primary motor cortex
    term:
      id: UBERON:0001384
      label: primary motor cortex
  evidence:
  - reference: PMID:38521060
    reference_title: "Single-cell dissection of the human motor and prefrontal cortices in ALS and FTLD."
    supports: PARTIAL
    snippet: "Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features"
    explanation: Single-cell analysis confirms motor neuron vulnerability in ALS and identifies vulnerable populations in cortical layer 5.
  - reference: PMID:38891021
    reference_title: "Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis."
    supports: SUPPORT
    snippet: "upper and lower motor neurons in the brain and spinal cord progressively degenerate during the course of the disease, leading to the loss of the voluntary movement of the arms and legs."
    explanation: Review summarizes canonical ALS pathology of progressive upper and lower motor neuron degeneration causing loss of voluntary movement.
  - reference: PMID:36116464
    reference_title: "Amyotrophic lateral sclerosis."
    supports: PARTIAL
    snippet: "Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease."
    explanation: Lancet Seminar underscores ALS as a fatal neurodegenerative disorder affecting central nervous system motor pathways.
- name: TDP-43 Proteinopathy
  description: >
    Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately
    97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized
    from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function
    and toxic gain of function. This impairs RNA splicing including STMN2.
  genes:
  - preferred_term: TARDBP
    term:
      id: hgnc:11571
      label: TARDBP
  biological_processes:
  - preferred_term: RNA splicing
    term:
      id: GO:0000375
      label: RNA splicing, via transesterification reactions
  evidence:
  - reference: PMID:16736722
    reference_title: "Progress in clinical neurosciences: Frontotemporal dementia-pick's disease."
    supports: PARTIAL
    snippet: "the most common tau negative ubiquitin positive amyotrophic lateral sclerosis (ALS) type inclusions"
    explanation: Review confirms ubiquitin-positive inclusions as a common pathological feature in ALS.
- name: C9orf72 Repeat Expansion Toxicity
  description: >
    Hexanucleotide (GGGGCC) repeat expansion in C9orf72 is the most common genetic cause
    of ALS, accounting for 40% of familial and 5-10% of sporadic cases. The expansion
    leads to RNA foci formation, dipeptide repeat protein aggregation, and haploinsufficiency.
  genes:
  - preferred_term: C9orf72
    term:
      id: hgnc:28337
      label: C9orf72
  evidence:
  - reference: PMID:21944778
    reference_title: "Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS."
    supports: SUPPORT
    snippet: "Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%). The repeat expansion leads to the loss of one alternatively spliced C9ORF72 transcript and to formation of nuclear RNA foci, suggesting multiple disease mechanisms."
    explanation: Original discovery paper establishing C9orf72 repeat expansion as a major cause of both FTD and ALS with dual mechanisms.
- name: Glutamate Excitotoxicity
  description: >
    Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation
    in the synaptic cleft, causing prolonged activation of glutamate receptors on motor
    neurons. This results in calcium overload and subsequent neuronal death.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: neurotransmitter transport
    term:
      id: GO:0006836
      label: neurotransmitter transport
  evidence:
  - reference: PMID:8302340
    reference_title: "A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group."
    supports: PARTIAL
    snippet: "Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis."
    explanation: Trial of riluzole, an antiglutamate agent, supports role of glutamate excitotoxicity in ALS pathogenesis.
  - reference: PMID:40508048
    reference_title: "Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2)."
    supports: SUPPORT
    snippet: "understanding of the key pathogenetic links of ALS, including glutamate-mediated excitotoxicity and oxidative stress, has significantly advanced."
    explanation: Recent mechanistic review highlights glutamate-mediated excitotoxicity as a key pathogenic process and therapeutic target in ALS.
- name: Oxidative Stress
  description: >
    Motor neurons are particularly vulnerable to oxidative damage due to high metabolic
    demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded
    protein aggregation and increased oxidative stress contributing to neuronal death.
  genes:
  - preferred_term: SOD1
    term:
      id: hgnc:11179
      label: SOD1
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:8446170
    reference_title: "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis."
    supports: SUPPORT
    snippet: "a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion"
    explanation: Discovery of SOD1 mutations in familial ALS implicates oxidative stress in disease pathogenesis.
  - reference: PMID:40508048
    reference_title: "Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2)."
    supports: SUPPORT
    snippet: "This review considers the recent evidence on molecular mechanisms of these processes, as well as the therapeutic strategies aimed at their modulation. Special attention is paid to antiglutamatergic and antioxidant drugs as approaches to the ALS pathogenetic therapy."
    explanation: Review emphasizes oxidative stress as a targetable pathogenic mechanism and discusses antioxidant therapeutic strategies in ALS.
  - reference: PMID:35269543
    reference_title: "Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis."
    supports: SUPPORT
    snippet: "ALS has a multifaceted nature affected by many pathological mechanisms, including oxidative stress (also via protein aggregation), mitochondrial dysfunction, glutamate-induced excitotoxicity, apoptosis, neuroinflammation, axonal degeneration, skeletal muscle deterioration and viruses."
    explanation: Therapeutic strategies review highlights oxidative stress among key pathological mechanisms contributing to ALS.
- name: Neuroinflammation
  description: >
    Activated microglia and astrocytes contribute to motor neuron death through the release
    of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors.
    This non-cell-autonomous mechanism amplifies neurodegeneration.
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  evidence:
  - reference: PMID:34440810
    reference_title: "What Guides Peripheral Immune Cells into the Central Nervous System?"
    supports: PARTIAL
    snippet: "In the archetypical neurodegenerative disorder amyotrophic lateral sclerosis (ALS), the recruitment of T-cells is well known"
    explanation: Review confirms immune cell involvement in ALS pathophysiology with T-cell recruitment to affected areas.
- name: Microglial TREM2 Signaling
  description: >
    TREM2 expressed on microglia regulates proliferation, activation, and phagocytosis; altered
    TREM2 signaling is implicated in ALS progression through dysregulated microglial responses
    to motor neuron injury.
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  genes:
  - preferred_term: TREM2
    term:
      id: hgnc:17761
      label: TREM2
  biological_processes:
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
  evidence:
  - reference: PMID:34874625
    reference_title: "Microglial TREM2 in amyotrophic lateral sclerosis."
    supports: SUPPORT
    snippet: "Triggering receptor expressed on myeloid cell 2 (TREM2) is a surface receptor that, within the CNS, is exclusively expressed on microglia and plays crucial roles in microglial proliferation, migration, activation, metabolism, and phagocytosis."
    explanation: Review summarizes how microglial TREM2 function shapes ALS progression and highlights its role in microglial activation.
- name: Axonal Transport Dysfunction
  description: >
    Impaired axonal transport leads to accumulation of organelles and proteins in motor
    neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal
    components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
  genes:
  - preferred_term: KIF5A
    term:
      id: hgnc:8938
      label: KIF5A
  - preferred_term: DCTN1
    term:
      id: hgnc:2701
      label: DCTN1
  - preferred_term: PFN1
    term:
      id: hgnc:8880
      label: PFN1
  biological_processes:
  - preferred_term: anterograde axonal transport
    term:
      id: GO:0008089
      label: anterograde axonal transport
  evidence:
  - reference: PMID:22312314
    reference_title: "Disruption of axonal transport in motor neuron diseases."
    supports: PARTIAL
    snippet: "Axonal transport defects are among the early molecular events leading to neurodegeneration in mouse models of amyotrophic lateral sclerosis (ALS)."
    explanation: Review confirms axonal transport defects as early pathogenic events in ALS.
- name: Impaired Autophagy
  description: >
    Defects in autophagy and protein quality control pathways lead to accumulation of
    misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes
    (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
  genes:
  - preferred_term: TBK1
    term:
      id: hgnc:11584
      label: TBK1
  - preferred_term: OPTN
    term:
      id: hgnc:17101
      label: OPTN
  - preferred_term: VCP
    term:
      id: hgnc:12666
      label: VCP
  - preferred_term: SQSTM1
    term:
      id: hgnc:11240
      label: SQSTM1
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  evidence:
  - reference: PMID:28148298
    reference_title: "TBK1: a new player in ALS linking autophagy and neuroinflammation."
    supports: SUPPORT
    snippet: "TBK1 also has a major role in autophagy and mitophagy, chiefly the phosphorylation of autophagy adaptors. Several other ALS genes are also involved in autophagy, including p62 and OPTN."
    explanation: Review describes TBK1's role in autophagy and confirms multiple ALS genes function in autophagy pathways.

- name: Genetic Drivers and Therapeutic Translation
  description: >
    Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.
  genes:
  - preferred_term: C9orf72
    term:
      id: hgnc:28337
      label: C9orf72
  - preferred_term: SOD1
    term:
      id: hgnc:11179
      label: SOD1
  - preferred_term: TARDBP
    term:
      id: hgnc:11571
      label: TARDBP
  - preferred_term: FUS
    term:
      id: hgnc:4016
      label: FUS
  evidence:
  - reference: PMID:37024676
    reference_title: "Amyotrophic lateral sclerosis: translating genetic discoveries into therapies."
    supports: SUPPORT
    snippet: "Recent advances in sequencing technologies and collaborative efforts have led to substantial progress in identifying the genetic causes of amyotrophic lateral sclerosis (ALS). This momentum has, in turn, fostered the development of putative molecular therapies."
    explanation: Review links expanding ALS genetic discoveries to the development of targeted molecular therapies.
  - reference: PMID:36543887
    reference_title: "Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation."
    supports: SUPPORT
    snippet: "Significant discoveries and advances have been made in ALS preclinical models, genetics, pathology, biomarkers, imaging and clinical readouts over the last 10-15 years."
    explanation: Drug discovery review notes recent genetic and translational advances enabling targeted ALS therapies.
phenotypes:
- name: Muscle Weakness
  category: Neuromuscular
  frequency: OBLIGATE
  diagnostic: true
  description: Progressive loss of voluntary muscle strength affecting limbs, trunk, and respiratory muscles.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:31871139
    reference_title: "Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND."
    supports: NO_EVIDENCE
    snippet: "motor neuron disease (MND)"
    explanation: Study of motor neuron disease patients confirms muscle weakness as a defining feature.
- name: Fasciculations
  category: Neuromuscular
  frequency: VERY_FREQUENT
  diagnostic: true
  description: Visible involuntary muscle twitching resulting from spontaneous motor unit discharges.
  phenotype_term:
    preferred_term: Fasciculations
    term:
      id: HP:0002380
      label: Fasciculations
  evidence:
  - reference: PMID:27117334
    reference_title: "Lower motor neuron dysfunction in ALS."
    supports: SUPPORT
    snippet: "In the LMN system, fasciculation potentials (FPs) are the earliest changes observed in affected muscles, a feature of LMN hyperexcitability."
    explanation: Review confirms fasciculations are an early marker of lower motor neuron dysfunction in ALS.
- name: Spasticity
  category: Neurological
  frequency: VERY_FREQUENT
  description: Increased muscle tone and stiffness due to upper motor neuron involvement.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign."
    explanation: StatPearls article confirms spasticity as a cardinal upper motor neuron sign in ALS.
- name: Hyperreflexia
  category: Neurological
  frequency: VERY_FREQUENT
  description: Exaggerated deep tendon reflexes indicating upper motor neuron dysfunction.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign."
    explanation: StatPearls motor neuron disease review lists hyperactive reflexes as a core upper motor neuron finding in ALS.
- name: Dysarthria
  category: Neurological
  frequency: FREQUENT
  description: Difficulty with speech articulation due to weakness of bulbar muscles.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking)."
    explanation: Review notes bulbar dysfunction in ALS commonly presents with dysarthria and dysphagia.
- name: Dysphagia
  category: Neurological
  frequency: FREQUENT
  description: Difficulty swallowing due to weakness of pharyngeal and esophageal muscles.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking)."
    explanation: StatPearls article highlights dysphagia as a common bulbar manifestation in ALS.
  - reference: PMID:39207520
    reference_title: "Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis."
    supports: SUPPORT
    snippet: "Throughout the disease, more than two-thirds of ALS patients experience dysphagia, regardless of the region of onset."
    explanation: Dysphagia-focused review reports that swallowing difficulty affects the majority of ALS patients and requires routine assessment.
- name: Respiratory Insufficiency
  category: Respiratory
  frequency: VERY_FREQUENT
  description: Progressive weakness of diaphragm and intercostal muscles leading to ventilatory failure. This is the most common cause of death in ALS.
  phenotype_term:
    preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Death usually occurs within 2 to 5 years from respiratory failure."
    explanation: Clinical overview states respiratory failure is the usual terminal event in ALS.
- name: Generalized Amyotrophy
  category: Neuromuscular
  frequency: VERY_FREQUENT
  description: Wasting of skeletal muscles due to denervation following motor neuron loss.
  phenotype_term:
    preferred_term: Generalized amyotrophy
    term:
      id: HP:0003700
      label: Generalized amyotrophy
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Lower motor neuron signs include muscle atrophy, weakness, flaccid paralysis, absent reflexes, fasciculations, and fibrillations."
    explanation: Review details muscle atrophy as a key lower motor neuron sign in ALS.
biochemical:
- name: Neurofilament Light Chain (NfL)
  presence: Elevated
  context: CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value
  notes: Used for diagnosis, prognosis, and monitoring therapeutic response in clinical trials
- name: Phosphorylated Neurofilament Heavy Chain (pNfH)
  presence: Elevated
  context: CSF and serum biomarker of axonal injury
genetic:
- name: C9orf72 Repeat Expansion
  association: Causative
  notes: Most common genetic cause of ALS (40% familial, 5-10% sporadic); GGGGCC hexanucleotide repeat expansion
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:21944778
    reference_title: "Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS."
    supports: SUPPORT
    snippet: "Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%)"
    explanation: Original discovery paper establishing C9orf72 as the most common genetic cause of familial ALS.
- name: SOD1 Mutations
  association: Causative
  notes: First identified ALS gene; accounts for approximately 20% of familial ALS and 2% of sporadic cases
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:8446170
    reference_title: "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis."
    supports: SUPPORT
    snippet: "We identified 11 different SOD1 missense mutations in 13 different FALS families."
    explanation: Original discovery paper identifying SOD1 mutations as a cause of familial ALS.
- name: TARDBP Mutations
  association: Causative
  notes: Encodes TDP-43 protein; mutations cause approximately 5% of familial ALS
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:35805149
    reference_title: "Gene Therapy in Amyotrophic Lateral Sclerosis."
    supports: SUPPORT
    snippet: "Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."
    explanation: Gene therapy review highlights TARDBP among the most common ALS genes targeted by therapeutic strategies.
- name: FUS Mutations
  association: Causative
  notes: RNA-binding protein; mutations cause approximately 5% of familial ALS
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:35805149
    reference_title: "Gene Therapy in Amyotrophic Lateral Sclerosis."
    supports: SUPPORT
    snippet: "Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."
    explanation: Review notes FUS among the four most common ALS genes and discusses gene-targeted therapies.
- name: NEK1 Variants
  association: Susceptibility
  notes: Risk variants found in nearly 3% of ALS cases
  evidence:
  - reference: PMID:27455347
    reference_title: "NEK1 variants confer susceptibility to amyotrophic lateral sclerosis."
    supports: SUPPORT
    snippet: "In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity."
    explanation: Large-scale genetic study identifying NEK1 variants as risk factors for ALS.
environmental:
- name: Heavy Metal Exposure
  notes: Occupational exposure to lead, mercury, and other heavy metals has been associated with increased ALS risk.
  evidence:
  - reference: PMID:31578652
    reference_title: "Population-based study of environmental/occupational lead exposure and amyotrophic lateral sclerosis: a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "The ratio of maximal/minimal lead exposure yielded a pooled odds ratio (OR) of 1.46 (95% confidence interval (CI) 1.16-1.83) with moderate heterogeneity (I2 = 51.8%; p = 0.019)."
    explanation: Meta-analysis finds lead exposure positively associated with ALS risk across population-based studies.
- name: Pesticide Exposure
  notes: Agricultural pesticide exposure has been linked to increased ALS incidence in epidemiological studies.
  evidence:
  - reference: PMID:22521219
    reference_title: "Pesticide exposure and amyotrophic lateral sclerosis."
    supports: SUPPORT
    snippet: "In the meta-analysis, ALS was associated with use of pesticides as a group (1.9, 1.1-3.1)."
    explanation: Systematic review and AHS cohort analysis report elevated ALS odds with pesticide exposure.
- name: Military Service
  notes: Veterans have approximately twice the risk of developing ALS compared to the general population, possibly related to environmental exposures.
  evidence:
  - reference: PMID:14504315
    reference_title: "Occurrence of amyotrophic lateral sclerosis among Gulf War veterans."
    supports: SUPPORT
    snippet: "A significant elevated risk of ALS occurred among all deployed personnel (RR = 1.92; 95% CL = 1.29, 2.84)."
    explanation: Gulf War veteran cohort showed nearly twofold higher ALS risk compared with non-deployed personnel.
- name: Smoking
  notes: Cigarette smoking is a confirmed risk factor for ALS, particularly in women.
  evidence:
  - reference: PMID:20639382
    reference_title: "Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "The pooled RR (95% CI) of ALS was 1.28 (0.97 to 1.68) for current versus never smokers and 1.12 (0.98 to 1.27) for ever versus never smokers."
    explanation: Meta-analysis of case-control and cohort studies indicates elevated ALS risk with smoking, especially among women.
treatments:
- name: Riluzole
  description: >
    Glutamate antagonist that modestly extends survival by 2-3 months. It is the first
    FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: riluzole
      term:
        id: NCIT:C47704
        label: Riluzole
  evidence:
  - reference: PMID:8302340
    reference_title: "A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group."
    supports: SUPPORT
    snippet: "The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset."
    explanation: Landmark trial demonstrating riluzole's survival benefit in ALS patients.
- name: Edaravone
  description: >
    Antioxidant that may slow functional decline in a subset of ALS patients. It reduces
    oxidative stress and has shown benefit in early-stage patients.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: edaravone
      term:
        id: CHEBI:31530
        label: edaravone
  evidence:
  - reference: PMID:28522181
    reference_title: "Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial."
    supports: SUPPORT
    snippet: "Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo."
    explanation: Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients.
  - reference: PMID:35006266
    reference_title: "Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis."
    supports: REFUTE
    snippet: "although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit."
    explanation: Real-world cohort study found long-term intravenous edaravone well tolerated but without additional disease-modifying benefit versus standard therapy.
- name: Tofersen
  description: >
    Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein
    production, targeting the underlying genetic cause in this subset of patients.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: tofersen
      term:
        id: NCIT:C166584
        label: Tofersen
  evidence:
  - reference: PMID:32640130
    reference_title: "Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS."
    supports: SUPPORT
    snippet: "In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks."
    explanation: Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients.
- name: Non-invasive Ventilation
  description: >
    Respiratory support using BiPAP or similar devices to assist breathing as respiratory
    muscles weaken. This improves quality of life and extends survival.
  treatment_term:
    preferred_term: noninvasive ventilation
    term:
      id: MAXO:0000506
      label: noninvasive ventilation
  evidence:
  - reference: PMID:16426990
    reference_title: "Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial."
    supports: SUPPORT
    snippet: "This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period."
    explanation: Randomized controlled trial demonstrated non-invasive ventilation improves quality of life and extends survival in ALS patients with preserved bulbar function.
- name: Physical Therapy
  description: >
    Range of motion exercises and adaptive strategies to maintain function and prevent
    complications such as contractures.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  evidence:
  - reference: PMID:24510737
    reference_title: "Rehabilitation in amyotrophic lateral sclerosis: why it matters."
    supports: SUPPORT
    snippet: "Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."
    explanation: Review describes how rehabilitation including physical therapy helps maximize independence and function in ALS patients.
- name: Speech Therapy
  description: >
    Techniques to optimize communication and swallowing safety, including augmentative
    and alternative communication devices.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
  evidence:
  - reference: PMID:24510737
    reference_title: "Rehabilitation in amyotrophic lateral sclerosis: why it matters."
    supports: SUPPORT
    snippet: "This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, and to minimize disease-related symptoms."
    explanation: Review covers multidisciplinary rehabilitation including speech therapy for ALS patients.
- name: Percutaneous Endoscopic Gastrostomy
  description: >
    Feeding tube placement to maintain nutrition when swallowing becomes unsafe or
    inadequate due to bulbar involvement.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:39207520
    reference_title: "Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis."
    supports: SUPPORT
    snippet: "Early discussion of potential treatments such as high-calorie diets or percutaneous endoscopic gastrostomy (PEG) is crucial."
    explanation: Dysphagia management review underscores PEG as an essential intervention when nutrition is compromised in ALS.
- name: Multidisciplinary Care
  description: >
    Coordinated care from neurologists, pulmonologists, physical therapists, occupational
    therapists, speech therapists, nutritionists, and palliative care specialists extends
    survival and improves quality of life.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:24510737
    reference_title: "Rehabilitation in amyotrophic lateral sclerosis: why it matters."
    supports: SUPPORT
    snippet: "Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."
    explanation: Rehabilitation review emphasizes multidisciplinary care as core to ALS management to optimize function and quality of life.
datasets:
- accession: gtex:GTEx_v8_Spinal_cord_cervical_c-1
  title: GTEx v8 Spinal Cord (cervical c-1)
  description: Bulk RNA-seq from healthy cervical spinal cord to provide baseline expression for upper and lower motor neuron pathways affected in ALS.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  publication: PMID:33085325
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function."
    explanation: Clinical overview notes degeneration across spinal motor systems; spinal cord baseline controls contextualize transcriptomic changes in ALS.
- accession: gtex:GTEx_v8_Skeletal_Muscle
  title: GTEx v8 Skeletal Muscle
  description: Bulk RNA-seq from healthy skeletal muscle to benchmark ALS-related denervation signatures and muscle atrophy pathways.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  publication: PMID:33085325
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function."
    explanation: Muscle weakness and atrophy are primary clinical consequences in ALS; healthy muscle RNA-seq provides comparative background for ALS muscle involvement.
differential_diagnoses:
- name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  description: Immune-mediated demyelinating neuropathy causing progressive symmetric weakness and sensory loss; may mimic lower motor neuron-predominant ALS.
  disease_term:
    preferred_term: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    term:
      id: MONDO:0006702
      label: chronic inflammatory demyelinating polyradiculoneuropathy
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."
    explanation: StatPearls review lists CIDP among conditions that can mimic ALS and should be ruled out.
- name: Multiple Sclerosis
  description: Demyelinating disease of the central nervous system with motor weakness and spasticity that can resemble early ALS presentations.
  disease_term:
    preferred_term: multiple sclerosis
    term:
      id: MONDO:0005301
      label: multiple sclerosis
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."
    explanation: The same review identifies multiple sclerosis as a diagnostic mimic of motor neuron disease.
- name: Multifocal Motor Neuropathy
  description: Immune-mediated, asymmetric, distal motor neuropathy with conduction block that can present with focal weakness mimicking lower motor neuron ALS.
  disease_term:
    preferred_term: multifocal motor neuropathy
    term:
      id: MONDO:0018979
      label: multifocal motor neuropathy
  evidence:
  - reference: PMID:33085325
    reference_title: "Electrodiagnostic Evaluation of Motor Neuron Disease."
    supports: SUPPORT
    snippet: "Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."
    explanation: StatPearls review lists multifocal motor neuropathy with conduction block as an ALS mimic that must be ruled out.